Published in Nat Neurosci on June 01, 2015
Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. Elife (2015) 1.41
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med (2016) 1.11
Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science (2016) 0.95
β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Front Pharmacol (2015) 0.94
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? J Exp Med (2016) 0.89
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem (2015) 0.86
Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. Front Aging Neurosci (2015) 0.86
APP Receptor? To Be or Not To Be. Trends Pharmacol Sci (2016) 0.85
Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. J Neurosci (2016) 0.84
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. JAMA Neurol (2016) 0.84
HSP70 protects human neuroblastoma cells from apoptosis and oxidative stress induced by amyloid peptide isoAsp7-Aβ(1-42). Cell Death Dis (2015) 0.83
Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. Int J Neuropsychopharmacol (2016) 0.82
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine (2016) 0.81
Aβ Clearance, "hub" of Multiple Deficiencies Leading to Alzheimer Disease. Front Aging Neurosci (2015) 0.81
Interplay of histidine residues of the Alzheimer's disease Aβ peptide governs its Zn-induced oligomerization. Sci Rep (2016) 0.80
Magnetite-Amyloid-β deteriorates activity and functional organization in an in vitro model for Alzheimer's disease. Sci Rep (2015) 0.80
Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. Neurobiol Dis (2016) 0.80
Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease. Neurotherapeutics (2017) 0.80
Cross-interactions between the Alzheimer Disease Amyloid-β Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis. J Biol Chem (2016) 0.79
Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation. Alzheimers Dement (Amst) (2016) 0.79
Depletion of TDP-43 decreases fibril and plaque β-amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. Acta Neuropathol (2016) 0.79
Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance. Acta Pharmacol Sin (2016) 0.79
Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. Cell Metab (2015) 0.78
Aging and Neurodegeneration: A Tangle of Models and Mechanisms. Aging Dis (2016) 0.78
Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology. Biochim Biophys Acta (2015) 0.78
Supramolecular Glycosylation Accelerates Proteolytic Degradation of Peptide Nanofibrils. J Am Chem Soc (2015) 0.78
Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes. Acta Neuropathol Commun (2016) 0.78
Alzheimer disease: modeling an Aβ-centered biological network. Mol Psychiatry (2016) 0.78
Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies. Cell Mol Neurobiol (2016) 0.77
A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. J Biol Chem (2016) 0.77
Loss of presenilin function is associated with a selective gain of APP function. Elife (2016) 0.77
Amyloid β-peptides interfere with mitochondrial preprotein import competence by a coaggregation process. Mol Biol Cell (2016) 0.77
Tau-mediated synaptic damage in Alzheimer's disease. Transl Neurosci (2015) 0.77
Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. Mol Psychiatry (2016) 0.77
Role of diffuse low-level heteroplasmy of mitochondrial DNA in Alzheimer's disease neurodegeneration. Front Aging Neurosci (2015) 0.76
Physiological and pathological roles of the γ-secretase complex. Brain Res Bull (2016) 0.76
Towards Personalized Intervention for Alzheimer's Disease. Genomics Proteomics Bioinformatics (2016) 0.76
Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research. J Alzheimers Dis (2016) 0.76
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76
Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener (2016) 0.76
Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer's mouse model. J Exp Med (2016) 0.76
Effects of Tooth Loss and the Apolipoprotein E ɛ4 Allele on Mild Memory Impairment in the Fujiwara-kyo Study of Japan: A Nested Case-Control Study. J Alzheimers Dis (2016) 0.75
Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers. J Alzheimers Dis (2016) 0.75
Tribbles Pseudokinase 3 Induces Both Apoptosis and Autophagy in Amyloid-β induced Neuronal Death. J Biol Chem (2016) 0.75
The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice. J Neurosci (2016) 0.75
Immunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in Mice. J Alzheimers Dis (2016) 0.75
[Not Available]. Can Geriatr J (2016) 0.75
The New Criteria for Alzheimer's Disease - Implications for Geriatricians. Can Geriatr J (2016) 0.75
Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimers Dement (Amst) (2016) 0.75
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol (2016) 0.75
Fluoxetine Prevents Aβ1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-β1. Front Pharmacol (2016) 0.75
Does selection for short sleep duration explain human vulnerability to Alzheimer's disease? Evol Med Public Health (2017) 0.75
Quercetin ameliorates Aβ toxicity in Drosophila AD model by modulating cell cycle-related protein expression. Oncotarget (2016) 0.75
Memory loss: Five new things. Neurol Clin Pract (2016) 0.75
Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. Curr Alzheimer Res (2016) 0.75
Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol (2016) 0.75
Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol (2017) 0.75
The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain. Eur J Epidemiol (2016) 0.75
Improvement of Electroacupuncture on APP/PS1 Transgenic Mice in Spatial Learning and Memory Probably due to Expression of Aβ and LRP1 in Hippocampus. Evid Based Complement Alternat Med (2016) 0.75
TREM2-ligand interactions in health and disease. J Mol Biol (2017) 0.75
The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific. Sci Rep (2016) 0.75
A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. Sci Rep (2017) 0.75
Amyloid β Modification: A Key to the Sporadic Alzheimer's Disease? Front Genet (2017) 0.75
Interactions of β-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease. Curr Opin Hematol (2017) 0.75
Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin (2017) 0.75
Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study. PLoS One (2017) 0.75
The Neural Basis for Sleep Regulation - Data Assimilation from Animal to Model. Conf Rec Asilomar Conf Signals Syst Comput (2017) 0.75
Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment. J Neuroinflammation (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Sleep drives metabolite clearance from the adult brain. Science (2013) 9.65
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature (2012) 8.10
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol (2010) 5.59
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (1990) 4.71
Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 4.53
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
REST and stress resistance in ageing and Alzheimer's disease. Nature (2014) 4.38
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet (1994) 3.67
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
A three-dimensional human neural cell culture model of Alzheimer's disease. Nature (2014) 3.48
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron (2014) 2.83
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J (2012) 2.72
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev (2010) 2.64
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol (2008) 2.32
APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain (2006) 2.23
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Autophagy failure in Alzheimer's disease--locating the primary defect. Neurobiol Dis (2011) 2.14
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Aging as an event of proteostasis collapse. Cold Spring Harb Perspect Biol (2011) 2.06
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
Genetic insights in Alzheimer's disease. Lancet Neurol (2013) 1.96
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci (2009) 1.88
The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology (2004) 1.87
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology (2010) 1.86
Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry (2004) 1.84
Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging (2000) 1.83
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet (2011) 1.75
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med (2014) 1.73
Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol (2014) 1.73
The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A (2001) 1.72
Impairment of paravascular clearance pathways in the aging brain. Ann Neurol (2014) 1.66
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol (2014) 1.63
Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener (2011) 1.58
Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci (2011) 1.53
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol (1998) 1.50
ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A (2013) 1.50
TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol (2014) 1.47
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
IKKβ deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. J Neurosci (2014) 1.44